Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. Takeuchi S, et al. Among authors: yano s. J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317. J Med Invest. 2017. PMID: 28955006 Free article. Clinical Trial.
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S. Fukuda K, et al. Among authors: yano s. Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8. Cancer Res. 2019. PMID: 30737231
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. Arai S, et al. Among authors: yano s. J Thorac Oncol. 2020 May;15(5):752-765. doi: 10.1016/j.jtho.2020.01.001. Epub 2020 Jan 21. J Thorac Oncol. 2020. PMID: 31972351 Free article.
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, Morise M, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Takeuchi S, et al. Among authors: yano s. Transl Lung Cancer Res. 2021 Jan;10(1):314-325. doi: 10.21037/tlcr-20-549. Transl Lung Cancer Res. 2021. PMID: 33569315 Free PMC article.
Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab.
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Sakaguchi H, et al. Among authors: yano s. Intern Med. 2022 Jan 1;61(1):75-79. doi: 10.2169/internalmedicine.7452-21. Epub 2021 Jun 26. Intern Med. 2022. PMID: 34176837 Free PMC article.
2,474 results